申联生物签订多联多价疫苗项目开发合同

Core Viewpoint - The company, Shenlian Biopharmaceutical (Shanghai) Co., Ltd., has signed a project contract with the Lanzhou Veterinary Research Institute to jointly develop multi-valent vaccines for swine and cattle, aiming to enhance disease prevention efficiency and reduce costs [1]. Group 1: Project Collaboration - The collaboration involves the development of multi-valent vaccines targeting three diseases for pigs and three for cattle, with both parties sharing the resulting technology and intellectual property [1]. - Each party will bear its respective costs as per the agreement, indicating a structured approach to resource allocation [1]. Group 2: Market Competitiveness - The anticipated vaccines are expected to achieve "one injection for four protections," which will reduce the number of immunizations required, thereby saving resources and costs while improving production efficiency [1]. - This initiative is projected to enhance the company's competitive edge in the animal health sector by providing comprehensive and efficient disease prevention solutions [1]. Group 3: Future Development Plans - The company plans to strengthen its collaboration with the Lanzhou Veterinary Research Institute, keeping pace with industry trends and accurately addressing changes in prevalent strains and clinical needs [1]. - Future efforts will focus on exploring the application potential of its R&D technology platform, accelerating breakthroughs in other multi-valent vaccines, mRNA vaccines, synthetic peptide vaccines, and virus-like particle (VLP) vaccines [1]. - The goal is to gradually form a clustered product matrix in disease prevention for pigs, ruminants, pets, and aquaculture, continuously enhancing the company's core competitiveness [1].